AGOMAB

Agomab to Participate in Upcoming Investor Conferences

Antwerp, Belgium, November 4, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming investor conferences:

- **Guggenheim 3rd Annual Healthcare Conference.** Fireside chat on Tuesday, November 10, 2026 at 3:30 PM ET in Boston, MA.
- **2026 Jefferies Global Healthcare Conference.** Wednesday, November 18, 2026 in London, UK.
- **9th Annual Evercore Healthcare Conference.** Fireside chat on Tuesday, December 1, 2026 at 4:15 PM ET in Miami, FL.
- **Piper Sandler 38th Annual Healthcare Conference.** Fireside chat on Thursday, December 3, 2026 at 12:30 PM ET in New York, NY.

About Agomab
Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab's product candidates are designed to target established, potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimizing safety liabilities. Fostering a culture of excellence, Agomab's mission is to pioneer therapeutics that aim to resolve fibro-inflammation and restore organ function to enable people with these disorders to live fuller and healthier lives.

Contacts
Investors
Sofie Van Gijsel
VP of Investor Relations
E-Mail: sofie.vangijsel@agomab.com
Phone: +1 781 296 1143

Media
Gretchen Schweitzer
Trophic Communications
E-Mail: agomab@trophic.eu
Phone: +49 172 861 8540